Distribution of authigenic albites in a limestone succession of the Helvetic Domain, eastern Switzerland

A new occurrence of authigenic albite was found in a Jurassic sedimentary succession of the Glarus Nappe near Walenstadt (eastern Switzerland). The euhedral shape and the chemical purity of these albites are evidence for their authigenic origin. The crystals are irregularly distributed in the sediment, highlighting the importance of the host rock composition for albite authigenesis. The crystals occur exclusively in limestones with a carbonate content higher than 80 wt-%. A diagenetic or hydrothermal origin of albite authigenesis is discussed for the studied region. Clay mineral transformation appears to be an important source of ions for albite formatio

Observations on the Formation of Massive Stars by Accretion

Observations of the H66a recombination line from the ionized gas in the cluster of newly formed massive stars, G10.6-0.4, show that most of the continuum emission derives from the dense gas in an ionized accretion flow that forms an ionized disk or torus around a group of stars in the center of the cluster. The inward motion observed in the accretion flow suggests that despite the equivalent luminosity and ionizing radiation of several O stars, neither radiation pressure nor thermal pressure has reversed the accretion flow. The observations indicate why the radiation pressure of the stars and the thermal pressure of the HII region are not effective in reversing the accretion flow. The observed rate of the accretion flow, 0.001 solar masses/yr, is sufficient to form massive stars within the time scale imposed by their short main sequence lifetimes. A simple model of disk accretion relates quenched HII regions, trapped hypercompact HII regions, and photo-evaporating disks in an evolutionary sequence

Azithromycin alters spatial and temporal dynamics of airway microbiota in idiopathic pulmonary fibrosis

BackgroundHigh bacterial burden in the lung microbiota predicts progression of idiopathic pulmonary fibrosis (IPF). Azithromycin (AZT) is a macrolide antibiotic known to alter the lung microbiota in several chronic pulmonary diseases, and observational studies have shown a positive effect of AZT on mortality and hospitalisation rate in IPF. However, the effect of AZT on the lung microbiota in IPF remains unknown.MethodsWe sought to determine the impact of a 3-month course of AZT on the lung microbiota in IPF. We assessed sputum and oropharyngeal swab specimens from 24 adults with IPF included in a randomised controlled crossover trial of oral AZT 500 mg 3 times per week. 16S rRNA gene amplicon sequencing and quantitative PCR (qPCR) were performed to assess bacterial communities. Antibiotic resistance genes (ARGs) were assessed using real-time qPCR.ResultsAZT significantly decreased community diversity with a stronger and more persistent effect in the lower airways (sputum). AZT treatment altered the temporal kinetics of the upper (oropharyngeal swab) and lower airway microbiota, increasing community similarity between the two sites for 1 month after macrolide cessation. Patients with an increase in ARG carriage had lower bacterial density and enrichment of the genusStreptococcus. In contrast, patients with more stable ARG carriage had higher bacterial density and enrichment inPrevotella.ConclusionsAZT caused sustained changes in the diversity and composition of the upper and lower airway microbiota in IPF, with effects on the temporal and spatial dynamics between the two sites

Kant, race, and natural history

This article presents a new argument concerning the relation between Kant’s theory of race and aspects of the critical philosophy. It argues that Kant’s treatment of the problem of the systematic unity of nature and knowledge in the Critique of Pure Reason and the Critique of the Power of Judgment can be traced back a methodological problem in the natural history of the period – that of the possibility of a natural system of nature. Kant’s transformation of the methodological problem from natural history into a set of philosophical (and specifically epistemological) problems proceeds by way of the working out of his own problem in natural history – the problem of the natural history of the human races – and specifically the problem of the unity in diversity of the human species, in response to which he develops a theory of race. This theory of race is, further, the first developed model of the use of teleological judgment in Kant’s work. The article thus argues that Kant’s philosophical position on the systematic unity of nature and of knowledge in the first and third Critiques, and his account and defense of teleological judgment, are developed out of problems first articulated in his solution to the problem of the unity in diversity of the human species – that is, in his theory of race. The article does not seek to establish that these aspects of the critical philosophy are therefore racialised. But it does demonstrate, against those who deny its salience to his philosophy, how the problem of the unity in diversity of the human species and Kant’s theory of race is significant for the development of aspects of the critical philosophy and thus contributes to their philosophical problematics

Evaluation de la stratégie de lutte contre le cancer en Suisse, Phase 2, 2002 : document de synthèse

[Table des matières] 1. Introduction. 2. Méthode. 3. Conclusions et recommandations générales. 3.1. Stratégie. 3.2. Conclusions et recommandations concernant la stratégie, les structures et le fonctionnement, la collaboration avec l'extérieur. 3.3. Les 4 programmes nationaux. 3.4. Conclusions et recommandations pour les 4 programmes nationaux. 3.5. Bilan de l'expérience de la mise en place du dépistage du sein. 3.6. Conclusions et recommandations pour la mise en place du dépistage du sein. 3.7. Les données à disposition pour le suivi et l'évaluation de la stratégie nationale de lutte contre le cancer. 3.8. Conclusions et recommandations pour le suivi et l'évaluation de la stratégie nationale de lutte contre le cancer. 4. Annexes: Résumés des études 1 à 7. Etude 1: Suivi du développement de la stratégie nationale. Studie 2: Prozessevaluation und Prozessdokumentation. Studie 3: Mammographie-Screening in der Schweiz : eine retrospektive Analyse zur Umsetzung. Studie 4: Sekundäre Analyse der verfügbaren Indikatoren zur Messung der Ergebnisse des nationalen Krebsbekämpfungsprogrammes. Etude 5: Quel ancrage local des actions de la Ligue suisse contre le cancer ? : l'exemple de la prévention du mélanome. Studie 6: Begleitevaluation der Pilotphase des Aktionsmonats Brustkrebs. Etude 7: Accompagnement psychosocial des personnes ayant un diagnostic de cancer : étude de deux cantons

Detection of Epileptogenic Cortical Malformations with Surface-Based MRI Morphometry

Magnetic resonance imaging has revolutionized the detection of structural abnormalities in patients with epilepsy. However, many focal abnormalities remain undetected in routine visual inspection. Here we use an automated, surface-based method for quantifying morphometric features related to epileptogenic cortical malformations to detect abnormal cortical thickness and blurred gray-white matter boundaries. Using MRI morphometry at 3T with surface-based spherical averaging techniques that precisely align anatomical structures between individual brains, we compared single patients with known lesions to a large normal control group to detect clusters of abnormal cortical thickness, gray-white matter contrast, local gyrification, sulcal depth, jacobian distance and curvature. To assess the effects of threshold and smoothing on detection sensitivity and specificity, we systematically varied these parameters with different thresholds and smoothing levels. To test the effectiveness of the technique to detect lesions of epileptogenic character, we compared the detected structural abnormalities to expert-tracings, intracranial EEG, pathology and surgical outcome in a homogeneous patient sample. With optimal parameters and by combining thickness and GWC, the surface-based detection method identified 92% of cortical lesions (sensitivity) with few false positives (96% specificity), successfully discriminating patients from controls 94% of the time. The detected structural abnormalities were related to the seizure onset zones, abnormal histology and positive outcome in all surgical patients. However, the method failed to adequately describe lesion extent in most cases. Automated surface-based MRI morphometry, if used with optimized parameters, may be a valuable additional clinical tool to improve the detection of subtle or previously occult malformations and therefore could improve identification of patients with intractable focal epilepsy who may benefit from surgery

Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period

Objectives: People with HIV (PWH) are at an increased risk of atherosclerotic cardiovascular disease. Suboptimal responses to statin therapy in PWH may result from antiretroviral therapies (ARTs). This open-label extension study aimed to evaluate the long-term safety and efficacy of evolocumab up to 52\u200aweeks in PWH. Design: This final analysis of a multinational, placebo-controlled, double-blind, randomized phase 3 trial evaluated the effect of monthly subcutaneous evolocumab 420\u200amg on low-density lipoprotein cholesterol (LDL-C) during the open-label period (OLP) following 24\u200aweeks of double-blind period in PWH with hypercholesterolemia/mixed dyslipidemia. All participants enrolled had elevated LDL-C or nonhigh-density lipoprotein cholesterol (non-HDL-C) and were on stable maximally tolerated statin and stable ART. Methods: Efficacy was assessed by percentage change from baseline in LDL-C, triglycerides, and atherogenic lipoproteins. Treatment-emergent adverse events (TEAEs) were examined. Results: Of the 467 participants randomized in the double-blind period, 451 (96.6%) received at least one dose of evolocumab during the OLP (mean age of 56.4\u200ayears, 82.5% male, mean duration with HIV of 17.4\u200ayears). By the end of the 52-week OLP, the overall mean (SD) percentage change in LDL-C from baseline was -57.8% (22.8%). Evolocumab also reduced triglycerides, atherogenic lipid parameters (non-HDL-C, apolipoprotein B, total cholesterol, very-low-density lipoprotein cholesterol, and lipoprotein[a]), and increased HDL-C. TEAEs were similar between placebo and evolocumab during the OLP. Conclusion: Long-term administration of evolocumab lowered LDL-C and non-HDL-C, allowing more PWH to achieve recommended lipid goals with no serious adverse events. Trail registration: NCT02833844. Video abstract: http://links.lww.com/QAD/C441